Press release
August 3, 2026
Keros Therapeutics Reports Second Quarter 2026 Financial Results
Keros Therapeutics, Inc. (KROS)
LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to